Literature DB >> 21979905

[Which components should living guidelines contain?].

L Weissbach1.   

Abstract

BACKGROUND: Due to rapidly developing knowledge guidelines should be regularly, i.e. annually, checked for validity and amended.
METHODS: Exemplified by the S3 guidelines on prostate cancer a contradiction between the need for updating and financial resources can be seen. Because the participating experts have only limited availability, the hurdles in the application procedure linked to bureaucracy should at least be dropped.
RESULTS: In the living guidelines on prostate cancer key questions on 13 updating and 5 primary points in question have been formulated and resolved. Examples of updating are imaging, active surveillance and high-intensity focused ultrasound and for primary points, the benefits of new markers and the results of proton therapy. The work, supported by other disciplines, the ÄZQ (Medical Center for Quality in Medicine) and the BPS (Federal Association of Prostate Self-help) should be finished by September 2011.

Entities:  

Mesh:

Year:  2012        PMID: 21979905     DOI: 10.1007/s00120-011-2714-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  5 in total

1.  Unnecessary imaging for the staging of low-risk prostate cancer is common.

Authors:  Hugh J Lavery; Jonathan S Brajtbord; Adam W Levinson; Fatima Nabizada-Pace; Matthew E Pollard; David B Samadi
Journal:  Urology       Date:  2010-10-08       Impact factor: 2.649

2.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

5.  Randomised prostate cancer screening trial: 20 year follow-up.

Authors:  Gabriel Sandblom; Eberhard Varenhorst; Johan Rosell; Owe Löfman; Per Carlsson
Journal:  BMJ       Date:  2011-03-31
  5 in total
  1 in total

1.  [Implementation of the S3 prostate cancer guideline in daily clinical practice: results of a survey among urologists].

Authors:  M Fröhner; C Khan; R Koch; S G Schorr; M Wirth
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.